ALLEGRA HIVES Drug Patent Profile

Which patents cover Allegra Hives, and when can generic versions of Allegra Hives launch?

Allegra Hives is a drug marketed by Chattem Sanofi and is included in one NDA.

The generic ingredient in ALLEGRA HIVES is fexofenadine hydrochloride. There are twenty-three drug master file entries for this compound. One hundred and three suppliers are listed for this compound. Additional details are available on the fexofenadine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Allegra Hives

A generic version of ALLEGRA HIVES was approved as fexofenadine hydrochloride by TEVA on September 1^st, 2005.

Summary for ALLEGRA HIVES

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	127
Clinical Trials:	35
Patent Applications:	1,782
DailyMed Link:	ALLEGRA HIVES at DailyMed

Recent Clinical Trials for ALLEGRA HIVES

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Food and Drug Administration (FDA)	Early Phase 1
University of California, San Francisco	Early Phase 1
University of Alabama at Birmingham	Phase 2

See all ALLEGRA HIVES clinical trials

Pharmacology for ALLEGRA HIVES

Drug Class	Histamine-1 Receptor Antagonist
Mechanism of Action	Histamine H1 Receptor Antagonists

US Patents and Regulatory Information for ALLEGRA HIVES

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chattem Sanofi	ALLEGRA HIVES	fexofenadine hydrochloride	TABLET;ORAL	020872-008	Jan 24, 2011		DISCN	Yes	No
Chattem Sanofi	ALLEGRA HIVES	fexofenadine hydrochloride	TABLET;ORAL	020872-009	Jan 24, 2011		OTC	Yes	Yes

Expired US Patents for ALLEGRA HIVES

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chattem Sanofi	ALLEGRA HIVES	fexofenadine hydrochloride	TABLET;ORAL	020872-009	Jan 24, 2011
Chattem Sanofi	ALLEGRA HIVES	fexofenadine hydrochloride	TABLET;ORAL	020872-009	Jan 24, 2011
Chattem Sanofi	ALLEGRA HIVES	fexofenadine hydrochloride	TABLET;ORAL	020872-009	Jan 24, 2011
Chattem Sanofi	ALLEGRA HIVES	fexofenadine hydrochloride	TABLET;ORAL	020872-008	Jan 24, 2011

International Patents for ALLEGRA HIVES

See the table below for patents covering ALLEGRA HIVES around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	812195
Germany	3005948
China	1090935
Germany	69527429

ALLEGRA HIVES Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Allegra Hives

Introduction to Allegra Hives

Allegra Hives, a product of Sanofi, is a widely recognized antihistamine medication used to treat symptoms associated with hives, allergic reactions, and other allergic conditions. Here, we will delve into the market dynamics and financial trajectory of Allegra Hives, highlighting key factors driving its growth and challenges it faces.

Market Size and Growth

The antihistamine market, which includes products like Allegra Hives, is projected to experience significant growth. The global antihistamine market is expected to register a Compound Annual Growth Rate (CAGR) of 7.70% from 2024 to 2029[1].

For Allegra specifically, the market size is influenced by the broader antihistamine market trends. The human antihistamine drug market, which Allegra is a part of, is anticipated to grow from USD 274.8 million in 2023 to USD 706.2 million by 2033, at a CAGR of 9.9%[3].

Key Drivers of Growth

Rising Allergy Prevalence

The increasing prevalence of allergies is a significant driver for the growth of Allegra Hives. According to the Asthma and Allergy Foundation of America, nearly one-third of American adults and over a quarter of American children suffer from seasonal allergies, eczema, or food allergies each year[1].

Innovations in Drug Research and Development

Continuous innovations in antihistamine research and development are crucial for market growth. Companies like Sanofi are investing heavily in R&D to introduce novel formulations and improve treatment efficacy. For instance, the FDA approval of Allegra Oral Suspension for pediatric patients highlights the ongoing efforts to expand treatment options[2].

Expansions of Healthcare Infrastructure

Improvements in healthcare infrastructure, particularly in regions like North America, are boosting the market. Increased access to healthcare and higher awareness about allergic disorders contribute to the growing demand for antihistamines like Allegra Hives[1][3].

Regional Analysis

North America

North America is a dominant region for the antihistamine market, including Allegra Hives. The region accounts for a significant share due to the high incidence of allergic conditions, improved healthcare infrastructure, and proactive healthcare approaches. For example, in the United States, around 60 million people are affected by allergic rhinitis symptoms annually[1].

Other Regions

While North America leads, other regions such as Europe and Asia Pacific are also experiencing growth. Europe, for instance, is seeing an increase in demand due to growing allergy rates and heightened consumer awareness of antihistamine alternatives[4].

Market Segmentation

Drug Type

Second-generation antihistamines, which include Allegra Hives, hold a significant market share due to their improved safety profiles and reduced sedative effects. In 2023, second-generation antihistamines accounted for over 62.7% of the market share[3].

Medication Type

Over-the-counter (OTC) drugs, such as Allegra Hives, are preferred by consumers, reflecting their accessibility and convenience. OTC drugs led with a 60.7% market share in 2023[3].

Indications

Allergy treatments dominate the market, capturing a significant share. Allegra Hives, being a treatment for hives and other allergic reactions, benefits from this trend. Allergy drugs accounted for 62.7% of the market share in 2023[3].

Challenges

Patent Expiry and Generic Drugs

The patent expiry of branded drugs and the introduction of generic alternatives pose a challenge to the market growth of Allegra Hives. This can lead to reduced market share and revenue for branded products[1].

Adverse Effects

Adverse effects associated with antihistamine drugs can also impede market growth. While Allegra Hives is generally well-tolerated, side effects such as vomiting, pyrexia, and diarrhea in certain age groups can affect consumer preference[2].

Strategic Activities and Partnerships

Companies are engaging in strategic activities to bolster market growth. For example, partnerships like Astepro Allergy's collaboration with Meghann Fahy to help patients suffering from allergies can increase the usage and adoption of antihistamines, including Allegra Hives[1].

Financial Projections

The financial trajectory for Allegra Hives is closely tied to the overall antihistamine market. With a projected CAGR of 7.70% from 2024 to 2029 and a broader market growth to USD 706.2 million by 2033, Allegra Hives is poised for significant financial growth. However, the exact financial projections for Allegra Hives specifically would depend on various factors including market share, competition, and consumer preferences.

Key Takeaways

• Growing Allergy Prevalence: Increasing allergy rates drive demand for antihistamines like Allegra Hives.
• Innovations and R&D: Continuous innovations in antihistamine research are crucial for market growth.
• Regional Dominance: North America leads the market due to high allergy incidence and improved healthcare infrastructure.
• Market Segmentation: Second-generation antihistamines and OTC drugs dominate the market.
• Challenges: Patent expiry, generic drugs, and adverse effects are key challenges.

FAQs

What is the current market size of the antihistamine market?

The antihistamine market is projected to register a CAGR of 7.70% during the forecast period (2024-2029), with the human antihistamine drug market expected to reach USD 706.2 million by 2033[1][3].

Who are the key players in the antihistamine market?

Key players include Johnson and Johnson, Novartis, Pfizer, Merck and Co., and Bayer[1].

Which region is the fastest growing in the antihistamine market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029)[1].

What are the common indications for Allegra Hives?

Allegra Hives is commonly used to treat symptoms associated with hives, allergic reactions, and other allergic conditions such as urticaria and atopic dermatitis[3].

What are the potential challenges for Allegra Hives in the market?

Challenges include patent expiry of branded drugs, introduction of generic drugs, and adverse effects associated with antihistamine drugs[1].

Cited Sources

1. Mordor Intelligence: Antihistamine Market Size & Share Analysis - Growth Trends
2. Sanofi: FDA approves ALLEGRA® (fexofenadine hydrochloride) oral suspension
3. Market.US: Human Antihistamine Drug Market Size | CAGR OF 9.9%
4. Cognitive Market Research: Fexofenadine market will grow at a CAGR of 4.80% from 2024 to 2031.